David Amsellem

Joon Lee

Swayampakula Ramakanth

Edward Nash

Asim Rana

Matthew Kaplan

Ramakanth Swayampakula

- Corcept Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for **relacorilant** to treat patients with **platinum-resistant ovarian cancer**.  **[1088856_07b2ed5fbc09478891e05d61be32b036_0]** 
- This submission is supported by positive data from pivotal Phase 3 ROSELLA and Phase 2 trials, which showed improved progression-free and overall survival for patients receiving relacorilant plus nab-paclitaxel, without increasing the safety burden.  **[1088856_07b2ed5fbc09478891e05d61be32b036_0]** 
- The U.S. Food and Drug Administration (FDA) is also reviewing relacorilant for platinum-resistant ovarian cancer, with a **PDUFA target action date of July 11, 2026**.  **[1088856_07b2ed5fbc09478891e05d61be32b036_0]** 
- Additionally, the FDA has assigned a PDUFA date of **December 30, 2025**, for relacorilant as a treatment for patients with hypercortisolism.  **[1088856_07b2ed5fbc09478891e05d61be32b036_0]**

CORCEPT THERAPEUTICS (CORT)